To date, high programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency (MMRd), MSI-H, and tumor mutation burden have been considered the predictive biomarkers for improved patient outcomes [6,8,9]. Here, CD274 is linked to neoplasm.